Who Owns Propecia?
Propecia is owned by Organon & Co., a publicly traded global healthcare company spun off from Merck & Co. in June 2021. Organon acquired Propecia as part of Merck's divestment of its established brands portfolio. The drug was originally developed by Merck and received FDA approval in 1997. Organon trades on NYSE under ticker OGN and is headquartered in Jersey City, New Jersey, USA.
Who Owns Propecia?
- Parent Company: Organon & Co.
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NYSE: OGN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Propecia | Organon & Co. | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Propecia on AmazonHistory of Propecia
- Founded: 1997
- Founders: Merck & Co. (internal development)
Propecia was developed by Merck & Co. through research into 5-alpha reductase inhibition. The active ingredient, finasteride, was initially developed and approved as Proscar (5mg) in 1992 for treating benign prostatic hyperplasia (BPH). Researchers discovered that finasteride at a lower 1mg dose could effectively treat male pattern hair loss (androgenetic alopecia) by inhibiting the conversion of testosterone to dihydrotestosterone (DHT).
Merck conducted extensive clinical trials demonstrating the drug's efficacy in stopping hair loss and promoting hair regrowth in men. The FDA approved Propecia (finasteride 1mg) on December 22, 1997, specifically for the treatment of male pattern hair loss on the vertex and anterior mid-scalp area in men only. The label explicitly contraindicates use in women of childbearing potential due to risk of external genitalia feminization in a male fetus.
Following its approval, Propecia quickly became one of the most prescribed hair loss medications globally. The drug represented a significant advancement in dermatology, offering patients an effective oral treatment for androgenetic alopecia where previously only topical minoxidil was available.
Merck obtained layered patent protection for finasteride, including the original composition-of-matter patent (U.S. Patent 4,760,071, granted 1988) and use patents for treating androgenetic alopecia. These patents provided exclusivity extending into the early 2010s. The last material Propecia patent expired in November 2013, opening the market to generic competition.
The first generic finasteride 1mg tablets received FDA approval in 2013, with multiple manufacturers entering the market within months. As of 2025, the FDA's Orange Book lists more than 40 approved generic finasteride products from manufacturers including Teva Pharmaceuticals, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Accord Healthcare, and Aurobindo Pharma. Generic finasteride 1mg is available for under $15 per month at major U.S. pharmacies, compared to Propecia's pre-generic price of approximately $70-100 per month.
In June 2021, Merck completed the spinoff of Organon & Co., transferring Propecia and other established brands to the new independent company. Organon now holds the marketing authorization for Propecia in global markets, with the brand generating approximately $127 million in revenue in 2021 according to Organon's financial filings.
Propecia has faced significant regulatory and legal challenges related to reported persistent sexual side effects. In 2012, the FDA required label updates to include warnings about potential sexual side effects that may continue after discontinuation. In 2018, the FDA expanded warnings to include depression. These label changes have affected both brand-name Propecia and generic finasteride products.
About Organon & Co.
Who owns Organon & Co.?
Organon & Co. is a publicly traded company listed on the New York Stock Exchange under ticker OGN. The company was created through a spin-off from Merck & Co. on June 3, 2021. Merck shareholders received one share of Organon for every ten Merck shares held. Shares are widely held by institutional investors, with no single shareholder exercising controlling influence. The company has a single class of common stock with no dual-class share structure. Interim CEO Joseph Morrissey has led the company since October 2025.
Why was Organon spun off from Merck?
Merck announced the spin-off in February 2020 to create two focused companies. Merck wanted to concentrate on its growth pillars in oncology, vaccines, and key products like Keytruda. The women's health, established brands, and biosimilars businesses, while generating $6.5 billion in 2020 revenue, were not central to Merck's long-term strategy. The spin-off was expected to deliver approximately $1.5 billion in incremental operating efficiencies for Merck over three years. In connection with the spin-off, Merck received a distribution of approximately $9 billion from Organon.
What is Organon's revenue?
Organon reported revenue of $6.2 billion in FY2025, down 3 percent from $6.4 billion in FY2024. Women's Health contributed $1.75 billion, Established Brands $3.69 billion, Biosimilars $691 million, and Other $82 million. Adjusted EBITDA was $1.91 billion, representing a 30.7 percent margin. Diluted EPS was $0.72, and adjusted diluted EPS was $3.66. For FY2026, the company guided to approximately $6.2 billion in revenue and approximately $1.9 billion in adjusted EBITDA.
What products does Organon own?
Organon owns over 70 medicines and products. Key women's health products include Nexplanon (contraceptive implant), NuvaRing (vaginal ring contraceptive), Cerazette (progestin-only pill), and Follistim AQ/Puregon (fertility treatment). Established brands include Propecia (finasteride for hair loss), Singulair (montelukast for asthma), Zetia, Arcoxia, and Renitec. Biosimilars include Renflexis, Ontruzant, and Hadlima. The dermatology portfolio includes VTAMA (tapinarof cream, acquired in October 2024), Diprosone, and Elocon.
Why did Organon's CEO resign?
CEO Kevin Ali resigned on October 26, 2025, after the company's audit committee completed an investigation into improper wholesaler sales practices for Nexplanon. The investigation found that certain US wholesalers were asked to purchase more Nexplanon than they needed at the end of multiple quarters in 2022, 2024, and 2025 to enable Organon to meet guidance and external revenue expectations. The board determined the practices were improper and that certain prior statements were inaccurate or incomplete. Ali agreed to forgo severance and equity-related retirement benefits. The company also terminated its head of US commercial and government affairs.
What is the JADA System divestiture?
In late 2025, Organon announced an agreement to divest its JADA System, a device for controlling postpartum uterine bleeding, to Laborie Medical Technologies for up to $465 million. The deal included $440 million upfront and up to $25 million in milestone payments based on 2026 revenue targets. The divestiture was completed on January 28, 2026, with approximately 100 employees transferring to Laborie. Organon acquired the JADA System through its 2021 acquisition of Alydia Health. The proceeds are being applied to debt reduction as part of the company's deleveraging efforts.
What is VTAMA?
VTAMA (tapinarof) cream is a non-steroidal topical treatment for plaque psoriasis in adults and atopic dermatitis in adults and children. Organon acquired VTAMA through its purchase of Dermavant Sciences Ltd. from Roivant Sciences, which closed on October 28, 2024. The total consideration was up to approximately $1.2 billion, including a $175 million upfront payment, a $75 million regulatory milestone, and up to $950 million in commercial milestones, plus tiered royalties. VTAMA is Organon's first major dermatology acquisition and represents the company's strategy of expanding into adjacent therapeutic areas.
- Founded: 2021
- Headquarters: Jersey City, New Jersey, USA
- Company Type: Publicly Traded
- Stock: NYSE: OGN
- Revenue: $6.2 billion (FY2025)
- Employees: Approximately 10,000
Where Is Propecia Made / Based?
- Headquarters: Jersey City, New Jersey, USA
Propecia Categories & Tags
Propecia Recalls & Controversies
Propecia has faced significant controversies and legal challenges related to its side effects, particularly concerning persistent sexual dysfunction reported by some users after discontinuing the medication.
The most significant controversy involves reports of persistent sexual side effects including erectile dysfunction, decreased libido, and depression that some men claim continued even after stopping Propecia treatment. These reports emerged in the late 2000s and led to hundreds of lawsuits against Merck (and later Organon as the successor owner).
In 2012, the FDA required updates to Propecia's label to include warnings about potential sexual side effects that may continue after discontinuation of the drug. In 2018, the FDA expanded warnings to include depression. These label changes apply to both brand-name Propecia and all generic finasteride products.
Hundreds of lawsuits were filed against Merck by men who claimed to experience lasting side effects. In 2012, these lawsuits were consolidated in New Jersey courts for centralized management. The litigation centered on whether Merck adequately warned patients and physicians about the potential for persistent side effects.
In September 2021, a patient advocacy group filed a lawsuit seeking to pull Propecia and its generic versions from the market, alleging that federal regulators failed to act on evidence linking the drug to depression, erectile dysfunction, and in some cases, suicide.
Organon (as successor to Merck for Propecia) has maintained that Propecia is safe and effective when used as directed, citing extensive clinical data. The company attributes reported persistent side effects to other factors and continues to market the medication with updated safety warnings. Generic versions of finasteride remain widely available.
A condition sometimes called "post-finasteride syndrome" (PFS) has been described in medical literature, though its existence, causes, and prevalence remain debated among researchers. Some studies have found persistent symptoms in a small subset of finasteride users, while others have not replicated these findings.
Brands Owned by Organon & Co.
Propecia Ownership: Pros & Cons
Advantages
- +Backed by Organon's global pharmaceutical infrastructure and regulatory compliance systems
- +Over 25 years of clinical data and post-market safety monitoring
- +FDA-approved treatment with demonstrated efficacy for male pattern hair loss
- +Generic finasteride available at low cost, increasing treatment accessibility
- +Widely recognized brand name among physicians and patients
- +Available in 140+ countries through Organon's global distribution network
Considerations
- -Generic competition has significantly reduced brand revenue since 2013 patent expiry
- -Persistent sexual side effects controversy has led to hundreds of lawsuits and FDA label warnings
- -Post-finasteride syndrome remains debated in medical literature
- -Not suitable for women of childbearing potential due to teratogenic risk
- -Requires prescription and ongoing medical supervision
- -Results vary significantly among individuals and require continuous use to maintain
Frequently Asked Questions About Propecia
Sources & Further Reading
- Organon & Co. Official Website -
- Merck Announces Completion of Organon Spinoff -
- Organon Form 8-K Filing (SEC) -
- Organon Form 10 FAQ (Spinoff Details) -
- Finasteride Patent History and Generic Timeline -
- FDA Propecia Label Information -
- Reuters Investigation: Propecia Lawsuits -
- DrugWatch Propecia Information -
- Organon 2021 Annual Results -
- EMEA Finasteride Marketing Authorization Records -
Competitors to Propecia
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Roche | Switzerland | 1982 | Mass market | Global | All Genders | |
| Viatris | USA | 1998 | Premium | Global | Mens |
Learn More About Competitors
Healthcare PharmaceuticalsAccutane
Owned by Roche
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
dermatologyacne-treatmentprescription
Healthcare PharmaceuticalsViagra
Owned by Viatris Inc.
Brand name for sildenafil citrate, the first oral erectile dysfunction treatment approved by the FDA in 1998. Originally developed by Pfizer, now owned by Viatris following the 2020 Upjohn spinoff and Mylan merger.
erectile-dysfunctionmens-healthprescription
Competitive Analysis
Market Positioning: Propecia competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Propecia
Looking for brands with different ownership structures? These similar brands are not owned by Organon & Co., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike Propecia which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Propecia which is under a publicly traded parent company.
Healthcare PharmaceuticalsBausch + Lomb
Owned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
contact-lensesvision-carebausch-lomb
Publicly Traded
Bausch + Lomb operates independently without a large parent corporation.
Healthcare PharmaceuticalsRetavase
Owned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
pharmaceuticalthrombolyticreteplase
Privately Owned
Retavase is privately owned, unlike Propecia which is under a publicly traded parent company.
Healthcare PharmaceuticalsAlcon
Owned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
eye-carecontact-lensesophthalmic
Publicly Traded
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsGE HealthCare
Owned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
healthcare-technologymedical-imagingdiagnostics
Publicly Traded
GE HealthCare operates independently without a large parent corporation.
Organon & Co. Stock Information
Jobs at Organon & Co.
Latest News About Propecia
Related Articles About Propecia
View more articles
Entertainment
Toy Brand Ownership: From LEGO to Hasbro
LEGO is family-owned by the Kirk Kristiansens. Hasbro and Mattel are Wall Street-owned. Bandai Namco owns Tamagotchi. Discover who owns the biggest toy brands and why it matters. Explore our database.
Who Brands StaffSep 4, 2026
ToysLegoHasbro
Pop Culture
Video Game Brands and Their Corporate Parents
EA sold for $55B to Saudi Arabia's PIF, Silver Lake and Kushner's Affinity. Microsoft bought Activision Blizzard for $75.4B. Tencent owns Riot, Supercell, and stakes in Epic. Sony bought Bungie for $3.6B. Discover video game brands and their corporate parents.
Who Brands StaffSep 3, 2026
Video GamesAcquisitionsEa
Pop Culture
Brands That Appeared in Super Bowl Ads Then Got Acquired
Poppi ran a Super Bowl ad in February 2025 and PepsiCo bought it for $1.95B. Grubhub debuted in Super Bowl LX after Wonder acquired it for $650M. WeatherTech ran its 14th ad. Discover brands that appeared in Super Bowl ads then got acquired.
Who Brands StaffSep 2, 2026
Super BowlAcquisitionsPoppi
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Brandpharmaceutical
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment